Pharmacology/Pharmaceutical Industry
Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.
18 Aug, 2021 | 09:04h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)
Commentary on Twitter (thread – click for more)
Mix and match vaccines, AZ then mRNA (@BioNTech_Group) achieves a very strong immune response against the Delta variant.
This is the 1st report to look at mix vs Delta, specifically.https://t.co/6N46cUh8HW @TheLancet pic.twitter.com/cvlHp2XtXJ— Eric Topol (@EricTopol) August 17, 2021
U.S. to recommend COVID vaccine boosters at 8 months.
18 Aug, 2021 | 09:02h | UTCSources: US to recommend COVID vaccine boosters at 8 months – Associated Press
See also: Biden administration expected to advise Covid booster shots for most Americans – CNN AND US experts expected to recommend Covid booster shots for all – The Guardian
Commentary on Twitter (thread – click for more)
This decision seems to reflect a common fallacy; trying to reason about whether we "need X" just based on what things are like without X, rather than how much X will do to help.
It's surprising to see it at play in a decision of such consequence.
— Wes Pegden (@WesPegden) August 17, 2021
Editorial: COVID-19 vaccine equity and booster doses – “by Aug 9, only 12·6 million of the 4·46 billion doses administered globally were in low-income countries”.
18 Aug, 2021 | 08:58h | UTCCOVID-19 vaccine equity and booster doses – The Lancet Infectious Diseases
See also: New waves, new variants, old inequity: a continuing COVID-19 crisis – BMJ Global Health
Editorial: The WHO is right to call a temporary halt to COVID vaccine boosters.
18 Aug, 2021 | 08:56h | UTCThe WHO is right to call a temporary halt to COVID vaccine boosters – Nature
Opinion | Go Ahead. Vaccinate the Kids. The risk of vaccinating children will never be zero, but the alternative is so much worse.
18 Aug, 2021 | 08:50h | UTCGo Ahead. Vaccinate the Kids. – The Atlantic
Systematic review: Systemic corticosteroids for the treatment of COVID‐19.
17 Aug, 2021 | 09:11h | UTCSystemic corticosteroids for the treatment of COVID‐19 – Cochrane Library
Commentary on Twitter (thread – click for more)
JUST PUBLISHED – Systemic #corticosteroids for the treatment of #COVID19 from @CochraneHaem – https://t.co/l4V993gLzj 1/5 pic.twitter.com/Vjk4aHXKFV
— The Cochrane Library (@CochraneLibrary) August 16, 2021
[Preprint] Full vaccination suppresses SARS-CoV-2 delta variant mutation frequency.
17 Aug, 2021 | 08:59h | UTCFull vaccination suppresses SARS-CoV-2 delta variant mutation frequency – medRxiv
Commentary: Research debunks myth that COVID vaccination promotes mutations – News Medical
Commentary on Twitter
Evidence that vaccinations successfully suppress viral mutations and that the unvaccinated are the source of the variants. https://t.co/U80T4JLO7A
"No one is safe until everyone is safe." pic.twitter.com/B2pVeMm96r— Daniel Griffin MD PhD (@DanielGriffinMD) August 15, 2021
Top antimicrobial stewardship intervention publications in 2020.
17 Aug, 2021 | 08:51h | UTC
COVID-19 long haulers – “With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions”.
17 Aug, 2021 | 08:57h | UTCCOVID-19 long haulers – Nature Biotechnology
Related: M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
Commentary on Twitter
A News Feature published in @NatureBiotech reports on how repurposed or repositioned medicines appear to be the best hope against long-COVID. https://t.co/Hc9s2tr8N8 pic.twitter.com/ue2sH4gWzT
— Nature Portfolio (@NaturePortfolio) August 16, 2021
Study finds editorialists in top journals with industry-related conflicts of interest were more likely to author an unduly favorable editorial for cancer drugs.
17 Aug, 2021 | 08:47h | UTC
RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.
17 Aug, 2021 | 08:50h | UTCOnce-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Related:
FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.
16 Aug, 2021 | 01:22h | UTCCommentaries:
CDC, FDA recommend COVID booster for immune-compromised – CIDRAP
FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT
Covid booster: US approves third jab for the immunocompromised – BBC
CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR
6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR
CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN
Commentary on Twitter
The Infectious Diseases Society of America (IDSA) supports the @FDA and @CDCgov's decision to authorize a supplemental vaccine dose for immunocompromised patients.
Read our statement: https://t.co/odzzSgIxnY pic.twitter.com/4PZfUwpjhM
— IDSA (@IDSAInfo) August 13, 2021
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
16 Aug, 2021 | 01:19h | UTCCOVID-19 Vaccines While Pregnant or Breastfeeding – Centers for Disease Control and Prevention
Related:
Opinion | Should pregnant women have a COVID vaccine? The evidence says it’s safe and effective.
Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to antibody responses in SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine.
16 Aug, 2021 | 01:15h | UTCCommentary (on the preprint): Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study – News Medical
Related: More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID. (studies on the subject)
Durability of Moderna vaccine–induced antibodies against SARS-CoV-2 variants.
16 Aug, 2021 | 01:13h | UTCDurability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants – Science
Commentary:
Moderna COVID-19 vaccine found to be still effective after six months – MedicalXpress
Moderna’s Covid-19 vaccine protects against Delta variant, study finds – CNN
Commentary on Twitter
The majority of individuals who received both doses of the mRNA-1273 (Moderna) vaccine maintained binding and functional antibodies against #SARSCoV2 variants for six months, a new Science study shows. https://t.co/jf98Rgasop pic.twitter.com/IN1cP33zxN
— Science Magazine (@ScienceMagazine) August 12, 2021
Study suggests a potential protective benefit from MMR and TDP vaccines in reducing the risk of severe Covid-19 infections.
16 Aug, 2021 | 01:04h | UTC
Commentary on Twitter
New @MedCellPress
Prior Measles-Mumps-Rubella (MMR) or Tetanus-Diptheria-Pertussis (Tdap) vaccination induces a T-cell response that overlaps with #SARSCoV2 and appears to offer some (~20-30%) protection from severe Covid-19https://t.co/fYT7Qole8s pic.twitter.com/hMkHXvNQYU— Eric Topol (@EricTopol) August 14, 2021
Opinion: Making vaccines available to other countries before offering domestic booster vaccinations.
13 Aug, 2021 | 09:48h | UTCMaking Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA
Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).
13 Aug, 2021 | 09:58h | UTC
Opinion: Time for a smart approach to boosters.
13 Aug, 2021 | 09:51h | UTCTime for a Smart Approach to Boosters – Think Global Health
Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.
13 Aug, 2021 | 09:47h | UTC
Commentary on Twitter
Honored Jama Onc has published our work. Please get yourself vaccinated for those in whom it does not work. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease https://t.co/BXkUQGMmbO via @JAMAOnc part of @JAMANetwork
— Tom Ollila (@OllilaTom) August 11, 2021
RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.
12 Aug, 2021 | 09:56h | UTCEditorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients
Related:
[Preprint] 3rd AstraZeneca shot gives strong immunity.
Commentaries on Twitter
https://twitter.com/hildabast/status/1425576801850433537
The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29
— NEJM (@NEJM) August 11, 2021
RCT: Evaluation of Moderna mRNA vaccine in adolescents.
12 Aug, 2021 | 09:58h | UTCEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine
Related:
Commentaries on Twitter
The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29
— NEJM (@NEJM) August 11, 2021
The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx
— Eric Topol (@EricTopol) August 11, 2021
Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.
12 Aug, 2021 | 09:54h | UTCModerna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC
Original Study 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv
Original Study 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv
Related:
[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.
12 Aug, 2021 | 09:53h | UTCRelated:
Commentary on Twitter
New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH— Eric Topol (@EricTopol) August 11, 2021
WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.
12 Aug, 2021 | 09:02h | UTCCommentary:
WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch
Related:
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
Commentary on Twitter (thread – click for more)
WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab— World Health Organization (WHO) (@WHO) August 11, 2021